-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18

Benzinga·05/07/2026 14:08:28
Listen to the news
Canaccord Genuity analyst Gary Nachman maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and lowers the price target from $21 to $18.